AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...

GSK plc (GSK, GSK.L) announced the European Medicine Agency's Committee for Medicinal Products for Human Use or CHMP has recommended ...

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Apellis Pharmaceuticals, Inc. (APLS) announced on Friday that the Committee for Medicinal Products for Human Use or CHMP of the ...

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended an update to Novo Nordisk’s ...

APLS stock falls as the CHMP confirms its June 2024 negative opinion on the regulatory filing for intravitreal pegcetacoplan to treat GA in the EU.

The CHMP initially adopted a negative opinion in January after finding it was unable to establish a positive balance of benefits and risks for Syfovre, but Apellis sought a re-examination and was able ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

EU CHMP recommends approval of Merck’s Keytruda regimens as treatment for patients with two types of gynaecologic cancers ...